{"disease":{"id":"angina","name":"angina","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":6},"drugs":{"marketed":[{"drug_id":"atorvastatin","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"atorvastatin","indication_name":"Prinzmetal angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"fragmin","indication_name":"Prophylaxis of Ischemic Complications in Unstable Angina and Non-Q-Wave MI","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"nicardipine-hydrochloride","indication_name":"Chronic stable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NICARDIPINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Calcium ion channels","drug_class":"Calcium channel blocker","quality_score":53,"revenue":null,"mechanism":"Nicardipine blocks calcium ion influx into vascular smooth muscle, causing relaxation with minimal effect on cardiac muscle."},{"drug_id":"metoprolol","indication_name":"Angina Pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopressor","generic_name":"metoprolol","company_name":"Generic (originally Ciba-Geigy/Novartis)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A","drug_class":"Beta-1 selective blocker","quality_score":58,"revenue":null,"mechanism":"Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand."},{"drug_id":"caduet","indication_name":"Chronic Stable Angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"caduet","indication_name":"Vasospastic Angina (Prinzmetal’s or Variant Angina)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"methylchromone","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Crodimyl","generic_name":"METHYLCHROMONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":"Crodimyl works by modulating the activity of a specific cellular pathway to improve blood flow to the heart."},{"drug_id":"molsidomine","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Motazomin","generic_name":"MOLSIDOMINE","company_name":"","drug_phase":"phase_2","molecular_target":"Estrogen receptor","drug_class":"molsidomine","quality_score":41,"revenue":null,"mechanism":"Molsidomine works by releasing nitric oxide, which relaxes blood vessels and improves blood flow to the heart."},{"drug_id":"trimetazidine","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vastarel","generic_name":"TRIMETAZIDINE","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"trimetazidine","quality_score":null,"revenue":null,"mechanism":"Trimetazidine works by optimizing the heart's energy production, reducing the amount of oxygen required by the heart muscle."},{"drug_id":"enoxaparin-sodium","indication_name":"Unstable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lovenox (Preservative Free)","generic_name":"ENOXAPARIN SODIUM","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Low Molecular Weight Heparin","quality_score":10,"revenue":null,"mechanism":"Lovenox works by enhancing the activity of antithrombin-III to inhibit blood clotting."},{"drug_id":"ranolazine","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ranexa","generic_name":"RANOLAZINE","company_name":"Menarini Intl","drug_phase":"marketed","molecular_target":"Sodium channel protein type 5 subunit alpha","drug_class":"Anti-anginal [EPC]","quality_score":75,"revenue":null,"mechanism":"Ranexa works by blocking the sodium channels in heart muscle cells to reduce the amount of calcium that enters the cells during heart contractions."},{"drug_id":"heparin","indication_name":"Prevention of Cardiac Ischemia in Unstable Angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"HEPARIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"Anti-coagulant","quality_score":56,"revenue":null,"mechanism":"Heparin works by binding to Antithrombin-III, a protein that inhibits the formation of blood clots."},{"drug_id":"bivalirudin","indication_name":"Unstable Angina Pectoris during PTCA","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Angiomax","generic_name":"BIVALIRUDIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"thrombin","drug_class":"Anti-coagulant [EPC]","quality_score":10,"revenue":null,"mechanism":"Bivalirudin directly inhibits thrombin by binding to its catalytic site and anion-binding exosite, preventing thrombus formation."},{"drug_id":"glyceryl-trinitrate","indication_name":"Angina Pectoris Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nitroglycerin","generic_name":"glyceryl trinitrate","company_name":"Fougera","drug_phase":"marketed","molecular_target":"guanylate cyclase","drug_class":"Nitrate Vasodilator [EPC]","quality_score":65,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, activating guanylate cyclase and increasing cyclic GMP, leading to smooth muscle relaxation and vasodilation."},{"drug_id":"glyceryl-trinitrate","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nitroglycerin","generic_name":"glyceryl trinitrate","company_name":"Fougera","drug_phase":"marketed","molecular_target":"guanylate cyclase","drug_class":"Nitrate Vasodilator [EPC]","quality_score":65,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, activating guanylate cyclase and increasing cyclic GMP, leading to smooth muscle relaxation and vasodilation."},{"drug_id":"ivabradine","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Corlanor","generic_name":"IVABRADINE","company_name":"Amgen","drug_phase":"marketed","molecular_target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1","drug_class":"Hyperpolarization-activated Cyclic Nucleotide-gated Channel Blocker","quality_score":43,"revenue":null,"mechanism":""},{"drug_id":"verapamil-hydrochloride","indication_name":"Vasospastic (Prinzmetal's variant) angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"verapamil-hydrochloride","indication_name":"Unstable (crescendo, pre-infarction) angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"verapamil-hydrochloride","indication_name":"Chronic stable angina (classic effort-associated angina)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"fragmin","indication_name":"Prophylaxis of ischemic complications in unstable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fragmin","generic_name":"Dalteparin Sodium","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Factor Xa and thrombin","drug_class":"Low molecular weight heparin (LMWH)","quality_score":68,"revenue":null,"mechanism":"Dalteparin enhances inhibition of Factor Xa and thrombin by antithrombin."},{"drug_id":"non-interventional-study","indication_name":"Angina Pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"nifedipine","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Procardia","generic_name":"NIFEDIPINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Dihydropyridine Calcium Channel Blocker [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"nifedipine","indication_name":"Prinzmetal angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Procardia","generic_name":"NIFEDIPINE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Dihydropyridine Calcium Channel Blocker [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"verapamil","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoptin","generic_name":"VERAPAMIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Calcium Channel Blocker","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"verapamil","indication_name":"Prinzmetal angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isoptin","generic_name":"VERAPAMIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Calcium Channel Blocker","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"metoprolol","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopressor","generic_name":"metoprolol","company_name":"Generic (originally Ciba-Geigy/Novartis)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A","drug_class":"Beta-1 selective blocker","quality_score":58,"revenue":null,"mechanism":"Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand."},{"drug_id":"nitroglycerin","indication_name":"Acute relief of angina pectoris due to coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NITROGLYCERIN","company_name":"","drug_phase":"marketed","molecular_target":"Nitric oxide synthase pathway","drug_class":"Nitrate Vasodilator [EPC]","quality_score":10,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, which activates guanylate cyclase, leading to increased cyclic GMP and subsequent vasodilation in smooth muscle."},{"drug_id":"heparin-sodium","indication_name":"Prevention of Cardiac Ischemia in Unstable Angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Heparin Sodium In Plastic Container","generic_name":"Heparin Sodium","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"Antithrombin III, Coagulation Factors Xa and IIa","drug_class":"Anticoagulant","quality_score":63,"revenue":null,"mechanism":"Heparin enhances Antithrombin III activity to inhibit coagulation factors Xa and IIa."},{"drug_id":"mibefradil","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Posicor","generic_name":"MIBEFRADIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent T-type calcium channel subunit alpha-1I","drug_class":"mibefradil","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"tilisolol","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Selecal","generic_name":"TILISOLOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"tilisolol","quality_score":null,"revenue":null,"mechanism":"Selecal works by blocking beta-1 adrenergic receptors in the heart, reducing heart rate and blood pressure."},{"drug_id":"tenitramine","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"tenitramine","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"Vasodilators Organic Nitrates","quality_score":null,"revenue":null,"mechanism":"Tenitramine works by releasing nitric oxide, which relaxes blood vessels and improves blood flow to the heart."},{"drug_id":"clonitrate","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dinitrochlorhydrin","generic_name":"CLONITRATE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Clonitrate works by relaxing blood vessels to improve blood flow to the heart."},{"drug_id":"celiprolol","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Selectol","generic_name":"CELIPROLOL","company_name":"","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"celiprolol","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"diltiazem","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cardizem","generic_name":"diltiazem","company_name":"Generic (originally Tanabe Seiyaku)","drug_phase":"marketed","molecular_target":"Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1","drug_class":"Calcium channel blocker (non-dihydropyridine, benzothiazepine)","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"diltiazem","indication_name":"Prinzmetal angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cardizem","generic_name":"diltiazem","company_name":"Generic (originally Tanabe Seiyaku)","drug_phase":"marketed","molecular_target":"Voltage-dependent calcium channel gamma-1 subunit, Multidrug resistance protein 1, Solute carrier family 22 member 1","drug_class":"Calcium channel blocker (non-dihydropyridine, benzothiazepine)","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"propranolol","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inderal","generic_name":"propranolol","company_name":"Generic (originally ICI/AstraZeneca)","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2","drug_class":"Non-selective beta-blocker","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"procardia-xl","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Procardia","generic_name":"Nifedipine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Dihydropyridine Calcium Channel Blocker [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"procardia-xl","indication_name":"Prinzmetal angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Procardia","generic_name":"Nifedipine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Voltage-dependent L-type calcium channel subunit alpha-1C","drug_class":"Dihydropyridine Calcium Channel Blocker [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"nadolol","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Corgard","generic_name":"NADOLOL","company_name":"Uswm","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta-Adrenergic Blocker [EPC]","quality_score":54,"revenue":null,"mechanism":""},{"drug_id":"isosorbide-mononitrate","indication_name":"Angina Pectoris Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monoket","generic_name":"ISOSORBIDE MONONITRATE","company_name":"","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1","drug_class":"Nitrate Vasodilator [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"isosorbide-mononitrate","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monoket","generic_name":"ISOSORBIDE MONONITRATE","company_name":"","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1","drug_class":"Nitrate Vasodilator [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lipitor","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"lipitor","indication_name":"Prinzmetal angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"eptifibatide","indication_name":"Unstable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Integrilin","generic_name":"EPTIFIBATIDE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Integrin alpha-IIb/beta-3","drug_class":"Platelet Aggregation Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Integrilin blocks the binding of fibrinogen to platelets, preventing them from clumping together and forming clots."},{"drug_id":"olmesartan","indication_name":"angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"olmesartan medoxomil-hydrochlorothiazide","generic_name":"OLMESARTAN","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":"Olmesartan works by blocking the action of a hormone that causes blood vessels to constrict, allowing blood vessels to relax and blood pressure to decrease."},{"drug_id":"hctz","indication_name":"angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lisinopril/HCTZ","generic_name":"HCTZ","company_name":"Direct_Rx","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"bepridil","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Org 5730","generic_name":"BEPRIDIL","company_name":"","drug_phase":"marketed","molecular_target":"Voltage-dependent P/Q-type calcium channel subunit alpha-1A","drug_class":"High Risk QT Prolonging Agents","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nicardipine","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cardene","generic_name":"NICARDIPINE","company_name":"Hikma Intl Pharms","drug_phase":"marketed","molecular_target":"Voltage-dependent T-type calcium channel subunit alpha-1H","drug_class":"Dihydropyridine Calcium Channel Blocker","quality_score":80,"revenue":null,"mechanism":"Cardene works by blocking calcium channels in the heart and blood vessels, which helps to relax and widen blood vessels, reducing blood pressure and heart workload."},{"drug_id":"atenolol","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tenoretic 100","generic_name":"ATENOLOL","company_name":"Twi Pharms","drug_phase":"marketed","molecular_target":"Adenosine receptor A3","drug_class":"beta-Adrenergic Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clopidogrel","indication_name":"Unstable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Plavix","generic_name":"clopidogrel","company_name":"Generic (originally Sanofi/BMS)","drug_phase":"marketed","molecular_target":"Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter","drug_class":"Thienopyridine antiplatelet agent","quality_score":55,"revenue":null,"mechanism":"Irreversibly blocks the P2Y12 ADP receptor on platelets, inhibiting platelet aggregation and preventing arterial thrombosis."},{"drug_id":"amlodipine","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvasc","generic_name":"amlodipine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6","drug_class":"Calcium channel blocker (dihydropyridine)","quality_score":55,"revenue":null,"mechanism":"Long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, reducing blood pressure and myocardial oxygen demand."},{"drug_id":"amlodipine","indication_name":"Prinzmetal angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Norvasc","generic_name":"amlodipine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6","drug_class":"Calcium channel blocker (dihydropyridine)","quality_score":55,"revenue":null,"mechanism":"Long-acting dihydropyridine calcium channel blocker that relaxes vascular smooth muscle, reducing blood pressure and myocardial oxygen demand."},{"drug_id":"lovenox","indication_name":"Unstable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lovenox","company_name":"University of Monastir","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"enoxaparin","indication_name":"Unstable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Enoxaparin","company_name":"Dana-Farber Cancer Institute","drug_phase":"marketed","molecular_target":"Antithrombin-III","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"integrilin","indication_name":"Unstable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"integrilin","company_name":"University of Cincinnati","drug_phase":"phase_1","molecular_target":"Integrin alpha-IIb/beta-3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nitroglycerine","indication_name":"Angina Pectoris Prevention","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"nitroglycerine","company_name":"University Hospital, Ghent","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1, Soluble guanylate cyclase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nitroglycerine","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"nitroglycerine","company_name":"University Hospital, Ghent","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1, Soluble guanylate cyclase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ranexa","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ranexa","company_name":"Midwest Cardiovascular Research Foundation","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Potassium voltage-gated channel subfamily H member 2, Sodium channel protein type 5 subunit alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"amlodipin","indication_name":"Angina pectoris","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amlodipin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"verapamil-hydrochloride","indication_name":"Angina at rest","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"amlodipin","indication_name":"Prinzmetal angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amlodipin","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Voltage-dependent calcium channel gamma-1 subunit, 5-hydroxytryptamine receptor 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"verapamil-hydrochloride","indication_name":"Chronic stable angina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."}],"pipeline":[],"offLabel":[],"totalMarketed":63,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04008173","title":"The International Survey of Acute Coronary Syndromes-ARCHIVES","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":130000,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT04097912","title":"Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels","phase":"","overall_status":"COMPLETED","enrollment_count":99999,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT07063147","title":"TTE Improves Clinical Management of Stable Chest Pain","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Tianjin Chest Hospital","has_results":false},{"nct_id":"NCT03840928","title":"PatientSpot Formerly Known as ArthritisPower","phase":"","overall_status":"UNKNOWN","enrollment_count":40000,"lead_sponsor_name":"Global Healthy Living Foundation","has_results":false},{"nct_id":"NCT01218776","title":"International Survey of Acute Coronary Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":36000,"lead_sponsor_name":"University of Bologna","has_results":false},{"nct_id":"NCT03781492","title":"Stable Angina Management and Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Silesian Centre for Heart Diseases","has_results":false},{"nct_id":"NCT06884436","title":"Preoperative Cardiology Consultation and the Incidence of Major Adverse Cardiac Events（MACE）","phase":"","overall_status":"COMPLETED","enrollment_count":22000,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT05255705","title":"Barts Revascularisation Registry","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT03421873","title":"Effectiveness and Safety of a Clinical Assessment and 0h/1h Troponin Rule-Out Protocol","phase":"","overall_status":"COMPLETED","enrollment_count":16000,"lead_sponsor_name":"Ulf Ekelund","has_results":false},{"nct_id":"NCT04022031","title":"Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine","phase":"","overall_status":"UNKNOWN","enrollment_count":12400,"lead_sponsor_name":"Tianjin University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT04026724","title":"Retrospective Clinical Study on Adjuvant Treatment of Coronary Heart Disease Angina Pectoris With Chinese Patent Medicine","phase":"","overall_status":"UNKNOWN","enrollment_count":12400,"lead_sponsor_name":"Tianjin University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT07353762","title":"Coronary Imaging and Metabolic Indicators-Based Risk Prediction Model for Coronary Artery Disease(CMI-RiskCAD)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10960,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT04044066","title":"Biomarker-based Prognostic Assessment","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT05719545","title":"A Cohort of Patients Undergoing Percutaneous Coronary Intervention","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Su Guohai","has_results":false},{"nct_id":"NCT06743672","title":"Development of a Novel Risk Prediction Tool for Emergency Department Patients Symptoms of Coronary Artery Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":6500,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT06614023","title":"Impact of Body Weight on Outcomes of Patients Undergoing Coronary Artery Bypass Grafting","phase":"","overall_status":"COMPLETED","enrollment_count":6448,"lead_sponsor_name":"Medical University of Silesia","has_results":false},{"nct_id":"NCT07471763","title":"Prospective Lifespan Cohort of Myocardial Infarction","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Fujian Provincial Hospital","has_results":false},{"nct_id":"NCT06075602","title":"COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Luzerner Kantonsspital","has_results":false},{"nct_id":"NCT05631769","title":"HOST - DAPT Duration According the Bleeding Risk","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4900,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT04718025","title":"Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":4500,"lead_sponsor_name":"Collegium Medicum w Bydgoszczy","has_results":false},{"nct_id":"NCT07359287","title":"Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":4500,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT05308329","title":"Kitasato PCI Registry","phase":"","overall_status":"UNKNOWN","enrollment_count":4500,"lead_sponsor_name":"Kitasato University","has_results":false},{"nct_id":"NCT06464042","title":"Influence of Air Quality on the Development and Progression of Premature Coronary Artery Disease","phase":"","overall_status":"RECRUITING","enrollment_count":4272,"lead_sponsor_name":"pablo Juan-Salvadores","has_results":false},{"nct_id":"NCT01674803","title":"Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)","phase":"NA","overall_status":"COMPLETED","enrollment_count":3514,"lead_sponsor_name":"Foundation of Cardiovascular Research and Education Enschede","has_results":false},{"nct_id":"NCT03216733","title":"SORT OUT X - Combo Stent Versus ORSIRO Stent","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3148,"lead_sponsor_name":"Aarhus University Hospital Skejby","has_results":false},{"nct_id":"NCT06583395","title":"Quest to Analyze One Thousand Humans Meditating","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3000,"lead_sponsor_name":"Tobias Moeller-Bertram","has_results":false},{"nct_id":"NCT06263439","title":"Surveillance of HFMD in Pediatric Outpatients","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT06384846","title":"AI Algorithms in Prediction of ACS Based on Leukocyte Properties","phase":"","overall_status":"RECRUITING","enrollment_count":2700,"lead_sponsor_name":"RobotDreams GmbH","has_results":false},{"nct_id":"NCT04682756","title":"A Multicenter Study on Early Diagnosis of NSTE-ACS Patients Based on Machine Learning Model","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"First Affiliated Hospital of Xinjiang Medical University","has_results":false},{"nct_id":"NCT06101862","title":"Coronary Computed Tomography Versus Invasive Angiography for Non-ST Elevation Acute Coronary Syndrome","phase":"NA","overall_status":"RECRUITING","enrollment_count":2300,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05380063","title":"Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2300,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT02601157","title":"Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2173,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03461484","title":"e-BioMatrix 6 Month DAPT France","phase":"","overall_status":"COMPLETED","enrollment_count":2098,"lead_sponsor_name":"Biosensors Europe SA","has_results":false},{"nct_id":"NCT03363035","title":"Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2055,"lead_sponsor_name":"Second Xiangya Hospital of Central South University","has_results":false},{"nct_id":"NCT03620760","title":"Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":2036,"lead_sponsor_name":"Xiaofan Wu","has_results":false},{"nct_id":"NCT04121949","title":"Cost-effectiveness and Safety of the CADScorSystem in Patients With Symptoms Suggestive of Stable Coronary Artery Disease.","phase":"NA","overall_status":"COMPLETED","enrollment_count":2016,"lead_sponsor_name":"Bispebjerg Hospital","has_results":false},{"nct_id":"NCT03752515","title":"A Registry Study on Genetics and Biomarkers of Acute Coronary Syndrome","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Beijing Institute of Heart, Lung and Blood Vessel Diseases","has_results":false},{"nct_id":"NCT06708000","title":"Personalized Evaluation of Susptected Myocardial Ischemia","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2000,"lead_sponsor_name":"Gødstrup Hospital","has_results":false},{"nct_id":"NCT04988685","title":"SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Luzerner Kantonsspital","has_results":false},{"nct_id":"NCT04347200","title":"REGistry of Long-term AnTithrombotic TherApy-1","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"National Medical Research Center for Cardiology, Ministry of Health of Russian Federation","has_results":false},{"nct_id":"NCT03486561","title":"Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"OBS Pakistan","has_results":false},{"nct_id":"NCT05482009","title":"Treatment of Angina Pectoris After Coronary Revascularization With Integrated Traditional Chinese and Western Medicine","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Jiangsu Famous Medical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT03392415","title":"The NOrdic-Baltic Randomized Registry Study for Evaluation of PCI in Chronic Total Coronary Occlusion","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Leif Thuesen","has_results":false},{"nct_id":"NCT06165406","title":"Distal Radial Access for Coronary Procedures","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Hospital Arnau de Vilanova","has_results":false},{"nct_id":"NCT01755520","title":"Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1893,"lead_sponsor_name":"Deutsches Herzzentrum Muenchen","has_results":false},{"nct_id":"NCT06545448","title":"Appropriateness of Angioplasty in Patients With Chronic Coronary Syndromes","phase":"","overall_status":"RECRUITING","enrollment_count":1875,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT04475380","title":"Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents","phase":"","overall_status":"COMPLETED","enrollment_count":1757,"lead_sponsor_name":"Foundation of Cardiovascular Research and Education Enschede","has_results":false},{"nct_id":"NCT02983123","title":"One-hour Troponin in a Low-prevalence Population of Acute Coronary Syndrome","phase":"","overall_status":"COMPLETED","enrollment_count":1750,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT03481712","title":"Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease 2","phase":"","overall_status":"COMPLETED","enrollment_count":1732,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06880133","title":"Expansion of SCG/GCG-Based CAD Sceering: Inclusion of Healthy Controls and CCTA Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":1600,"lead_sponsor_name":"Heart Force Medical Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}